clindamycin hydrochloride

01 02 03

General content

Your present location:General content

Clindamycin Hydrochloride-associated colitis

Number of visits:961 Date:2015/12/18 3:06:34
Clindamycin Hydrochloride-associated colitis
A prospective study of 200 consecutive patients receiving Clindamycin Hydrochloride (Cleocin HCl) for various reasons showed a 21% incidence of diarrhea and a 10% incidence of pseudomembranous colitis. The total dosage of Clindamycin Hydrochloride before the onset of diarrhea and the clinical syndrome associated with the diarrhea were of little help in differentiating those patients with or without pseudomembranous colitis. Pseudomembranous colitis developed most frequently after orally administered Clindamycin Hydrochloride, but was also seen with Clindamycin Hydrochloride parenterally administered. Early proctoscopic examination is necessary to diagnose colitis and is the most accurate means of detecting pseudomembranes; rectal biopsy results can confirm the diagnosis and delineate the degree of inflammation present. When the diagnosis is made soon after the onset of diarrhea, and the antibiotic is stopped, the pseudomembranous colitis seems to be self-limiting with no mortality.
Failure of Clindamycin Hydrochloride treatment of methicillin-resistant Staphylococcus aureus expressing inducible Clindamycin Hydrochloride resistance in vitro.
We report a case of a surgical site infection caused by Clindamycin Hydrochloride-susceptible, erythromycin-resistant methicillin-resistant Staphylococcus aureus (MRSA) that did not respond to treatment with Clindamycin Hydrochloride. The MRSA isolate obtained after treatment was resistant to Clindamycin Hydrochloride but was found to be identical by pulsed-field gel electrophoresis to the Clindamycin Hydrochloride-susceptible isolate obtained before treatment. A post hoc erythromycin-induction test (D test) confirmed the presence of in vitro inducible macrolide0002lincosamide0002streptogramin B resistance (iMLS) in the pretreatment isolate. Erythromycin induction testing confirmed in vitro iMLS in 90 (56%) of 161 erythromycin-resistant, clindamycillin-susceptible S. aureus isolates from pediatric patients. Our clinical laboratory currently tests all S. aureus isolates for iMLS before reporting Clindamycin Hydrochloride susceptibility.
Previous post:
Clindamycin Hydrochloride treatment of invasive infections

Next post:
Clindamycin Hydrochloride-associated colitis due to a toxin-producing species
Welcome to our website!BACK TO HOME >>